Everest Medicines Announces Approval of Trodelvy® in Ch

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...

Related Keywords

Yang Shi , Hunan , China , Taiwan , Shanghai , United States , Hong Kong , Singapore , Beijing , Hong Kong Special Administrative Region , Hong Kong General , South Korea , Chinese , Binghe Xu , Asia Pacific , Kevin Guo , Kerry Blanchard , Sacituzumab Govitecan , Health Sciences Authority Of Singapore , Drug Administration , National New Drug Anti , Cancer Clinical Research Centre , Gilead Sciences Inc , Chinese Academy Of Engineering , China National Medical Products Administration , Department Of Health , Ministry Of Food , First Product , Receive Regulatory Approval , Everest Plans , Launch Commercial Sales , National Medical Products Administration , New Drug Application , Priority Review , Chief Executive Officer , Drug Evaluation , Chief Medical Officer , Chinese Academy , National New Drug , Clinical Research Centre , Chief Commercial Officer , Drug Safety , Fast Track Designation , Orphan Drug Designation , Taiwan Food , Rare Severe Disease Priority Review Designation , Health Sciences Authority , Triple Negative Breast Cancer , Gilead Sciences , Everest Medicines , Greater China , Southeast Asian , Standardized Diagnosis , Advanced Breast Cancer , Breast Cancer Diagnosis , Chinese Society , Clinical Oncology , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , International Medical Approval , New Products Amp Services ,